NCT03663920 (INAPROACTIVE) is a clinical trial in HIV, sponsored by Ina-Respond.

Who is sponsoring NCT03663920?

NCT03663920 is sponsored by Ina-Respond.

Is NCT03663920 still recruiting?

NCT03663920 is currently completed. Last updated 13 November 2023.

Last reviewed 2023-11-13 · How we verify

NCT03663920: INAPROACTIVE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIV Infection and Risk Related Coinfections/Comorbidities in Indonesia

Completed Last updated 13 November 2023

What this trial tests

trial in HIV in 4,336 participants. Completed in 30 September 2023.

Timeline

9 January 2018

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Ina-Respond
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,336
Start date	9 January 2018
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	19 locations across Indonesia

Conditions studied

HIV — all drugs for HIV →

Sponsor

Ina-Respond — full company profile →

Who can join

Eligibility, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

INA-PROACTIVE is a multicenter, prospective, observational cohort study of HIV positive antiretroviral-naïve and treatment-experienced individuals. No investigational treatment or intervention will be used by this study. All participants will be managed according to the Indonesian HIV/AIDS Treatment Guideline and/or the Standard of Care (SoC) in local clinical setting, with the addition of rapid HIV viral load, CD4 cell count and syphilis testing.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Maintaining international research collaborations in the setting of a pandemic: Approach in Indonesia.
Karyana M, Kosasih H, Neal AT, Lau CY. · · 2021 · cited 3× · PMID 34326986 · DOI 10.7189/jogh.11.03087
A prospective observational cohort study of HIV infection in Indonesia: baseline characteristics and one-year mortality.
Merati TP, Yunihastuti E, Wisaksana R, Kurniati N, et al · · 2025 · cited 1× · PMID 39833697 · DOI 10.1186/s12879-024-10354-8
Development of a multiassay algorithm (MAA) to identify recent HIV infection in newly diagnosed individuals in Indonesia.
Wulan WN, Yunihastuti E, Arlinda D, Merati TP, et al · · 2023 · cited 1× · PMID 37854696 · DOI 10.1016/j.isci.2023.107986
Protocol for the identification of recent HIV infection in newly diagnosed individuals.
Wulan WN, Lokida D, Yunihastuti E, Kosasih H, et al · · 2026 · PMID 42133492 · DOI 10.1016/j.xpro.2026.104504
Annual trends and risk factors of late presentation of HIV at 19 referral hospitals in Indonesia: findings from the INA-PROACTIVE cohort.
Arlinda D, Yunihastuti E, Indrati AR, Merati TP, et al · · 2026 · PMID 41808690 · DOI 10.1016/j.lansea.2026.100742

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Ina-Respond trials

Trials by the same sponsor.

NCT04339179 — Observational Research on Infectious Disease Outbreaks and Difficult Cases of Unidentified Etiology in Indonesia · completed
NCT04535856 — Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients · Phase 1 · completed
NCT04613271 — Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia · Phase 3 · completed
NCT03870204 — Validation of POC-CCA Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum · completed
NCT04331782 — Integration of Mental Health in HIV Clinic to Increase the Success of ARV Treatment in PLWHA in Hospitals · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03663920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ina-Respond
Last refreshed: 13 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03663920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing